Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge (Q33362237)

26 July 2017

Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge (English)

1 reference

26 July 2017

Kahl LE

1

1 reference

26 July 2017

Thompson ME

series ordinal

2

1 reference

26 July 2017

Griffith BP

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 1989

1 reference

American Journal of Medicine

26 July 2017

1 reference

26 July 2017

87

1 reference

26 July 2017

3

1 reference

26 July 2017

289-294

1 reference

The incidence of gout in renal transplant recipients

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Side effects of systemic cyclosporine in patients not undergoing transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Gout and hyperuricaemia in patients on cyclosporin and diuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Preliminary criteria for the classification of the acute arthritis of primary gout

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

7 January 2021

Hyperuricemia and gout

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Cyclosporine: Five Years' Experience in Cadaveric Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Liver transplantation with use of cyclosporin a and prednisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Cyclosporine-associated chronic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Cyclosporine and prostaglandins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Reversibility of cyclosporin nephrotoxicity after three months' treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Hyperuricemia and uric acid nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Renal tubular function in cyclosporine-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Serum uric acid in essential hypertension: an indicator of renal vascular involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Renal syndromes associated with nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Colchicine in acute gout. Reassessment of risks and benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Colchicine myopathy and neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980153-6

10.1016/S0002-9343(89)80153-6

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference